235 related articles for article (PubMed ID: 21145912)
1. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
Granadillo M; Vallespi MG; Batte A; Mendoza O; Soria Y; Lugo VM; Torrens I
Vaccine; 2011 Jan; 29(5):920-30. PubMed ID: 21145912
[TBL] [Abstract][Full Text] [Related]
2. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
[TBL] [Abstract][Full Text] [Related]
3. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
4. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
Salehi M; Taheri T; Mohit E; Zahedifard F; Seyed N; Taslimi Y; Sattari M; Bolhassani A; Rafati S
Immunotherapy; 2012 Nov; 4(11):1107-20. PubMed ID: 23194361
[TBL] [Abstract][Full Text] [Related]
7. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
[TBL] [Abstract][Full Text] [Related]
8. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
[TBL] [Abstract][Full Text] [Related]
11. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
Demurtas OC; Massa S; Ferrante P; Venuti A; Franconi R; Giuliano G
PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
[TBL] [Abstract][Full Text] [Related]
13. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
[TBL] [Abstract][Full Text] [Related]
14. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150.
Chen S; Ou R; Tang J; Deng X; Wu Y; van Velkinburgh JC; Ni B; Xu Y
Cancer Epidemiol; 2013 Apr; 37(2):172-8. PubMed ID: 23127963
[TBL] [Abstract][Full Text] [Related]
15. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
Li YL; Liu J; Liu JN; Zhang J
Vaccine; 2011 Aug; 29(35):5959-62. PubMed ID: 21722685
[TBL] [Abstract][Full Text] [Related]
16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
17. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
Shahbazi S; Bolhassani A
Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
[TBL] [Abstract][Full Text] [Related]
18. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
Lee YS; Lee CW; Song MJ; Ho EM; Kim CJ; Park TC; Kim TG; Park JS
Acta Obstet Gynecol Scand; 2011 Dec; 90(12):1350-6. PubMed ID: 21916856
[TBL] [Abstract][Full Text] [Related]
20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]